Key nodes of a microRNA network associated with the integrated mesenchymal subtype of high-grade serous ovarian cancer

Chinese Journal of Cancer

Volumn 34, Issue 1, 2015, Pages 28-40

  Sun, Yan ^a   Guo, Fei ^a   Bagnoli, Marina ^b   Xue, Feng Xia ^a   Sun, Bao Cun ^a   Shmulevich, Ilya ^c   Mezzanzanica, Delia ^b   Chen, Ke Xin ^a   Sood, Anil K ^d   Yang, Da ^e   Zhang, Wei ^d  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Epithelial to mesenchymal transition (EMT); MicroRNA (miRNA); miR 101; miR 506; Ovary

Indexed keywords

BETA1 INTEGRIN; BRG1 PROTEIN; CYCLOOXYGENASE 2; DESMOCOLLIN; DNA METHYLTRANSFERASE 3A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE 2; KRUPPEL LIKE FACTOR 6; MICRORNA; MICRORNA 101; MICRORNA 128; MICRORNA 141; MICRORNA 182; MICRORNA 200A; MICRORNA 25; MICRORNA 29C; MICRORNA 506; MINICHROMOSOME MAINTENANCE PROTEIN 7; MITOGEN ACTIVATED PROTEIN KINASE 1; NERVE CELL ADHESION MOLECULE; SIRTUIN 1; SMAD7 PROTEIN; SONIDEGIB; STAT3 PROTEIN; TRANSCRIPTION FACTOR EZH2; TRANSFORMING GROWTH FACTOR BETA; UBIQUITIN CONJUGATING ENZYME E2; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VIMENTIN;

CANCER GROWTH; CANCER MORTALITY; CELL DEDIFFERENTIATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM TUMOR; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FRAGILE X SYNDROME; GENE EXPRESSION; GENE REGULATORY NETWORK; HUMAN; METASTASIS; OVARY CANCER; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR CLASSIFICATION; TUMOR GROWTH; UPREGULATION; CYSTADENOCARCINOMA; FEMALE; GENETICS; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY;

CYSTADENOCARCINOMA, SEROUS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MICRORNAS; OVARIAN NEOPLASMS;

EID: 84920271064     PISSN: None     EISSN: 1944446X     Source Type: Journal    
DOI: 10.5732/cjc.014.10284     Document Type: Review

References (142)

1. [1] Huang T, Alvarez A, Hu B, et al. Noncoding RNAs in cancer and cancer stem cells. Chin J Cancer, 2013, 32:582-593.
2. [2] Taranger CK, Noer A, Sorensen AL, et al. Induction of dedifferen-tiation, genomewide transcriptional programming, and epigenetic reprogramming by extracts of carcinoma and embryonic stemcells. Mol Biol Cell, 2005, 16:5719-5735.
3. [3] Lu M, Jolly MK, Levine H, et al. MicroRNA-based regulation ofepithelial-hybrid-mesenchymal fate determination. Proc Natl AcadSci U S A, 2013, 110:18144-18149.
4. [4] Ubil E, Duan J, Pillai IC, et al. Mesenchymal-endothelial transitioncontributes to cardiac neovascularization. Nature, 2014, 514:585-590.
5. [5] Lopez-Novoa JM, Nieto MA. Inflammation and EMT: an alliancetowards organ fibrosis and cancer progression. EMBO Mol Med, 2009, 1:303-314.
6. [6] Chung CH, Parker JS, Ely K, et al. Gene expression profiles identifyepithelial-to-mesenchymal transition and activation of nuclearfactor-kappaB signaling as characteristics of a high-risk head andneck squamous cell carcinoma. Cancer Res, 2006, 66:8210-8218.
7. [7] Joyce T, Cantarella D, Isella C, et al. A molecular signature forEpithelial to Mesenchymal transition in a human colon cancer cellsystem is revealed by large-scale microarray analysis. Clin ExpMetastasis, 2009, 26:569-587.
8. [8] Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, et al. Characterization of a naturally occurring breast cancer subsetenriched in epithelial-to-mesenchymal transition and stem cellcharacteristics. Cancer Res, 2009, 69:4116-4124.
9. [9] Kim J, Hong SJ, Park JY, et al. Epithelial-mesenchymal transitiongene signature to predict clinical outcome of hepatocellularcarcinoma. Cancer Sci, 2010, 101:1521-1528.
10. [10] Cheng WY, Kandel JJ, Yamashiro DJ, et al. A multi-cancermesenchymal transition gene expression signature is associatedwith prolonged time to recurrence in glioblastoma. PLoS One, 2012, 7:e34705.
11. [11] Cheng Q, Chang JT, Gwin WR, et al. A signature of epithelial-mesenchymal plasticity and stromal activation in primary tumormodulates late recurrence in breast cancer independent of diseasesubtype. Breast Cancer Res, 2014, 16:407.
12. [12] Gujral TS, Chan M, Peshkin L, et al. A noncanonical frizzled2pathway regulates epithelial-mesenchymal transition andmetastasis. Cell, 2014, 159:844-856.
13. [13] Cancer Genome Atlas Research Network. Integrated genomicanalyses of ovarian carcinoma. Nature, 2011, 474:609-615.
14. [14] Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion andmetastasis: a role for epithelial-mesenchymal transition? CancerRes, 2005, 65:5991-5995.
15. [15] Tarin D, Thompson EW, Newgreen DF. The fallacy of epithelialmesenchymal transition in neoplasia. Cancer Res, 2005, 65:5996-6000.
16. [16] Lee JM, Dedhar S, Kalluri R, et al. The epithelial-mesenchymaltransition: new insights in signaling, development, and disease. JCell Biol, 2006, 172:973-981.
17. [17] Steinestel K, Eder S, Schrader AJ, et al. Clinical significance ofepithelial-mesenchymal transition. Clin Transl Med, 2014, 3:17.
18. [18] Chai S, Ma S. Clinical implications of microRNAs in liver cancerstem cells. Chin J Cancer, 2013, 32:419-426.
19. [19] Bruce JP, Liu FF. MicroRNAs in nasopharyngeal carcinoma. Chin JCancer, 2014, 33:539-544.
20. [20] Hassan O, Ahmad A, Sethi S, et al. Recent updates on the role ofmicroRNAs in prostate cancer. J Hematol Oncol, 2012, 5:9.
21. [21] Del Vescovo V, Grasso M, Barbareschi M, et al. MicroRNAs as lungcancer biomarkers. World J Clin Oncol, 2014, 5:604-620.
22. [22] Kinose Y, Sawada K, Nakamura K, et al. The role of microRNAs inovarian cancer. Biomed Res Int, 2014, 2014:249393.
23. [23] Sun E, Shi Y. MicroRNAs: Small molecules with big roles in neurodevelopment and diseases. Exp Neurol, 2014, pii: S0014-4886(14)00257-X. doi: 10.1016/j.expneurol.2014.08.005. [Epub ahead of print].
24. [24] Matuszcak C, Haier J, Hummel R, et al. MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World J Gastroenterol, 2014, 20:13658-13666.
25. [25] Fortunato O, Boeri M, Verri C, et al. Therapeutic use of microRNAs in lung cancer. Biomed Res Int, 2014, 2014:756975.
26. [26] Budhu A, Ji J, Wang XW. The clinical potential of microRNAs. J Hematol Oncol, 2010, 3:37.
27. [27] Ding XM. MicroRNAs: regulators of cancer metastasis and epithelial-mesenchymal transition (EMT). Chin J Cancer, 2014, 33:140-147.
28. [28] Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell, 2013, 23:186-199.
29. [29] Sun Y, Hu L, Zheng H, et al. MiR-506 inhibits multiple targets in the epithelial-to-mesenchymal transition network and is associated with good prognosis in epithelial ovarian cancer. J Pathol, 2015, 235:25-36.
30. [30] Arora H, Qureshi R, Park WY. miR-506 regulates epithelial mesenchymal transition in breast cancer cell lines. PLoS One, 2013, 8:e64273.
31. [31] Santoro MR, Bray SM, Warren ST. Molecular mechanisms of fragile X syndrome: a twenty-year perspective. Annu Rev Pathol, 2012, 7:219-245.
32. [32] Bagnoli M, De Cecco L, Granata A, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget, 2011, 2:1265-1278.
33. [33] Rodriguez MI, Peralta-Leal A, O’Valle F, et al. PARP-1 regulates metastatic melanoma through modulation of vimentin-induced malignant transformation. PLoS Genet, 2013, 9:e1003531.
34. [34] Liu G, Sun Y, Ji P, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol, 2014, 233:308-318.
35. [35] Hao L, Ha JR, Kuzel P, et al. Cadherin switch from E- to N-cadherin in melanoma progression is regulated by the PI3K/PTEN pathway through Twist and Snail. Br J Dermatol, 2012, 166:1184-1197.
36. [36] Balli D, Ustiyan V, Zhang Y, et al. Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition. EMBO J, 2013, 32:231-244.
37. [37] Yin M, Ren X, Zhang X, et al. Selective killing of lung cancer cells by miRNA-506 molecule through inhibiting NF-kappaB p65 to evoke reactive oxygen species generation and p53 activation. Oncogene, 2014, doi: 10.1038/onc.2013.597. [Epub ahead of print].
38. [38] Kuphal S, Bosserhoff AK. Influence of the cytoplasmic domain of E-cadherin on endogenous N-cadherin expression in malignant melanoma. Oncogene, 2006, 25:248-259.
39. [39] Min C, Eddy SF, Sherr DH, et al. NF-kappaB and epithelial to mesenchymal transition of cancer. J Cell Biochem, 2008, 104:733-744.
40. [40] Graf F, Mosch B, Koehler L, et al. Cyclin-dependent kinase 4/6(cdk4/6) inhibitors: perspectives in cancer therapy and imaging. Mini Rev Med Chem, 2010, 10:527-539.
41. [41] Leonard JP, LaCasce AS, Smith MR, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood, 2012, 119:4597-4607.
42. [42] Dickson MA, Tap WD, Keohan ML, et al. Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma. J Clin Oncol, 2013, 31:2024-2028.
43. [43] Flaherty KT, Lorusso PM, Demichele A, et al. Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin Cancer Res, 2012, 18:568-576.
44. [44] Wen SY, Lin Y, Yu YQ, et al. miR-506 acts as a tumor suppressor by directly targeting the hedgehog pathway transcription factor Gli3 in human cervical cancer. Oncogene, 2014, doi: 10.1038/onc.2013.597. [Epub ahead of print].
45. [45] Zhao Z, Ma X, Hsiao TH, et al. A high-content morphological screen identifies novel microRNAs that regulate neuroblastoma cell differentiation. Oncotarget, 2014, 5:2499-2512.
46. [46] Zhang L, Volinia S, Bonome T, et al. Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A, 2008, 105:7004-7009.
47. [47] Cui J, Eldredge JB, Xu Y, et al. MicroRNA expression and regulation in human ovarian carcinoma cells by luteinizing hormone. PLoS One, 2011, 6:e21730.
48. [48] Hu Z, Lin Y, Chen H, et al. MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun, 2013, 435:82-87.
49. [49] Caponi S, Funel N, Frampton AE, et al. The good, the bad and the ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol, 2013, 24:734-741.
50. [50] Semaan A, Qazi AM, Seward S, et al. MicroRNA-101 inhibits growth of epithelial ovarian cancer by relieving chromatin-mediated transcriptional repression of p21(waf(1)/cip(1)). Pharm Res, 2011, 28:3079-3090.
51. [51] Liu L, Guo J, Yu L, et al. miR-101 regulates expression of EZH2 and contributes to progression of and cisplatin resistance in epithelial ovarian cancer. Tumour Biol, 2014, Sep 27. [Epub ahead of print].
52. [52] Guo F, Cogdell D, Hu L, et al. miR-101 suppresses the epithelial-to-mesenchymal transition by targeting ZEB1 and ZEB2 in ovarian carcinoma. Oncol Rep, 2014, 31:2021-2028.
53. [53] Wei X, Xiang T, Ren G, et al. miR-101 is down-regulated by the hepatitis B virus x protein and induces aberrant DNA methylation by targeting DNA methyltransferase 3A. Cell Signal, 2013, 25:439-446.
54. [54] Lin C, Huang F, Li QZ, et al. miR-101 suppresses tumor proliferation and migration, and induces apoptosis by targeting EZH2 in esophageal cancer cells. Int J Clin Exp Pathol, 2014, 7:6543-6550.
55. [55] Lei Q, Shen F, Wu J, et al. miR-101, downregulated in retinoblastoma, functions as a tumor suppressor in human retinoblastoma cells by targeting EZH2. Oncol Rep, 2014, 32:261-269.
56. [56] Wang L, Li L, Guo R, et al. miR-101 promotes breast cancer cellapoptosis by targeting Janus kinase 2. Cell Physiol Biochem, 2014, 34:413-422.
57. [57] Manvati S, Mangalhara KC, Kalaiarasan P, et al. miR-101 InducesSenescence and Prevents Apoptosis in the Background of DNADamage in MCF7 Cells. PLoS One, 2014, 9:e111177.
58. [58] Liang X, Liu Y, Zeng L, et al. miR-101 inhibits the G1-to-S phasetransition of cervical cancer cells by targeting Fos. Int J GynecolCancer, 2014, 24:1165-1172.
59. [59] Liu JJ, Lin XJ, Yang XJ, et al. A novel AP-1/miR-101 regulatoryfeedback loop and its implication in the migration and invasion ofhepatoma cells. Nucleic Acids Res, 2014, 42:12041-12051.
60. [60] Yao YL, Ma J, Wang P, et al. miR-101 acts as a tumor suppressorby targeting kruppel-like factor 6 in glioblastoma stem cells. CNSNeurosci Ther, 2014, doi: 10.1111/cns.12321. [Epub ahead ofprint].
61. [61] Yan F, Shen N, Pang J, et al. Restoration of miR-101 suppresseslung tumorigenesis through inhibition of DNMT3a-dependent DNAmethylation. Cell Death Dis, 2014, 5:e1413.
62. [62] Bu Q, Fang Y, Cao Y, et al. Enforced expression of miR-101enhances cisplatin sensitivity in human bladder cancer cellsby modulating the cyclooxygenase-2 pathway. Mol Med Rep, 2014, 10:2203-2209.
63. [63] Strillacci A, Valerii MC, Sansone P, et al. Loss of miR-101 expressionpromotes Wnt/beta-catenin signalling pathway activation andmalignancy in colon cancer cells. J Pathol, 2013, 229:379-389.
64. [64] Carvalho J, van Grieken NC, Pereira PM, et al. Lack ofmicroRNA-101 causes E-cadherin functional deregulationthrough EZH2 up-regulation in intestinal gastric cancer. J Pathol, 2012, 228:31-44.
65. [65] Varambally S, Cao Q, Mani RS, et al. Genomic loss of microRNA-101leads to overexpression of histone methyltransferase EZH2 incancer. Science, 2008, 322:1695-1699.
66. [66] Castilla MA, Diaz-Martin J, Sarrio D, et al. MicroRNA-200 familymodulation in distinct breast cancer phenotypes. PLoS One, 2012, 7:e47709.
67. [67] Hur K, Toiyama Y, Takahashi M, et al. MicroRNA-200c modulatesepithelial-to-mesenchymal transition (EMT) in human colorectalcancer metastasis. Gut, 2013, 62:1315-1326.
68. [68] Gregory PA, Bert AG, Paterson EL, et al. The miR-200 family andmiR-205 regulate epithelial to mesenchymal transition by targetingZEB1 and SIP1. Nat Cell Biol, 2008, 10:593-601.
69. [69] Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1promotes tumorigenicity by repressing stemness-inhibitingmicroRNAs. Nat Cell Biol, 2009, 11:1487-1495.
70. [70] Bracken CP, Gregory PA, Kolesnikoff N, et al. A double-negativefeedback loop between ZEB1-SIP1 and the microRNA-200family regulates epithelial-mesenchymal transition. Cancer Res, 2008, 68:7846-7854.
71. [71] Mizuguchi Y, Specht S, Lunz JG 3rd, et al. Cooperation of p300and PCAF in the control of microRNA 200c/141 transcription andepithelial characteristics. PLoS One, 2012, 7:e32449.
72. [72] Chang CJ, Chao CH, Xia W, et al. p53 regulates epithelial-mesen-chymal transition and stem cell properties through modulatingmiRNAs. Nat Cell Biol, 2011, 13:317-323.
73. [73] Schubert J, Brabletz T. p53 Spreads out further: suppression ofEMT and stemness by activating miR-200c expression. Cell Res, 2011, 21:705-707.
74. [74] Fu J, Rodova M, Nanta R, et al. NPV-LDE-225 (Erismodegib) inhibitsepithelial mesenchymal transition and self-renewal of glioblastomainitiating cells by regulating miR-21, miR-128, and miR-200. NeuroOncol, 2013, 15:691-706.
75. [75] Guo L, Chen C, Shi M, et al. Stat3-coordinated Lin-28-let-7-HMGA2and miR-200-ZEB1 circuits initiate and maintain oncostatin M-drivenepithelial-mesenchymal transition. Oncogene, 2013, 32:5272-5282.
76. [76] Kong D, Li Y, Wang Z, et al. miR-200 regulates PDGF-D-mediatedepithelial-mesenchymal transition, adhesion, and invasion ofprostate cancer cells. Stem Cells, 2009, 27:1712-1721.
77. [77] Bao B, Wang Z, Ali S, et al. Notch-1 induces epithelial-mesenchymaltransition consistent with cancer stem cell phenotype in pancreaticcancer cells. Cancer Lett, 2011, 307:26-36.
78. [78] Sureban SM, May R, Qu D, et al. DCLK1 regulates pluripotencyand angiogenic factors via microRNA-dependent mechanisms inpancreatic cancer. PLoS One, 2013, 8:e73940.
79. [79] Martello G, Rosato A, Ferrari F, et al. A microRNA targeting dicer formetastasis control. Cell, 2010, 141:1195-1207.
80. [80] Li BL, Lu C, Lu W, et al. miR-130b is an EMT-related microRNA thattargets DICER1 for aggression in endometrial cancer. Med Oncol, 2013, 30:484.
81. [81] Li M, Guan X, Sun Y, et al. miR-92a family and their target genes intumorigenesis and metastasis. Exp Cell Res, 2014, 323:1-6.
82. [82] Mendell JT. miRiad roles for the miR-17-92 cluster in developmentand disease. Cell, 2008, 133:217-222.
83. [83] Liu Y, Zhang Y, Wen J, et al. A genetic variant in the promoterregion of miR-106b-25 cluster and risk of HBV infection andhepatocellular carcinoma. PLoS One, 2012, 7:e32230.
84. [84] Kunej T, Godnic I, Ferdin J, et al. Epigenetic regulation ofmicroRNAs in cancer: an integrated review of literature. Mutat Res, 2011, 717:77-84.
85. [85] Schulte JH, Horn S, Otto T, et al. MYCN regulates oncogenicMicroRNAs in neuroblastoma. Int J Cancer, 2008, 122:699-704.
86. [86] Aguda BD, Kim Y, Piper-Hunter MG, et al. MicroRNA regulationof a cancer network: consequences of the feedback loopsinvolving miR-17-92, E2F, and Myc. Proc Natl Acad Sci U S A, 2008, 105:19678-19683.
87. [87] Zhao ZN, Bai JX, Zhou Q, et al. TSA suppresses miR-106b-93-25cluster expression through downregulation of MYC and inhibitsproliferation and induces apoptosis in human EMC. PLoS One, 2012, 7:e45133.
88. [88] Smith AL, Iwanaga R, Drasin DJ, et al. The miR-106b-25 clustertargets Smad7, activates TGF-beta signaling, and induces EMTand tumor initiating cell characteristics downstream of Six1 inhuman breast cancer. Oncogene, 2012, 31:5162-5171.
89. [89] Petrocca F, Visone R, Onelli MR, et al. E2F1-regulated microRNAsimpair TGFbeta-dependent cell-cycle arrest and apoptosis ingastric cancer. Cancer Cell, 2008, 13:272-286.
90. [90] Kan T, Sato F, Ito T, et al. The miR-106b-25 polycistron, activated bygenomic amplification, functions as an oncogene by suppressingp21 and Bim. Gastroenterology, 2009, 136:1689-1700.
91. [91] Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/ miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res, 2008, 68:8191-8194.
92. [92] Xu X, Chen Z, Zhao X, et al. MicroRNA-25 promotes cell migration and invasion in esophageal squamous cell carcinoma. Biochem Biophys Res Commun, 2012, 421:640-645.
93. [93] Chen ZL, Zhao XH, Wang JW, et al. MicroRNA-92a promotes lymph node metastasis of human esophageal squamous cell carcinoma via E-cadherin. J Biol Chem, 2011, 286:10725-10734.
94. [94] Fang WK, Liao LD, Li LY, et al. Down-regulated desmocollin-2 promotes cell aggressiveness through redistributing adherens junctions and activating beta-catenin signalling in oesophageal squamous cell carcinoma. J Pathol, 2013, 231:257-270.
95. [95] Poliseno L, Salmena L, Riccardi L, et al. Identification of the miR-106b~25 microRNA cluster as a proto-oncogenic PTEN-targeting intron that cooperates with its host gene MCM7 in transformation. Sci Signal, 2010, 3:ra29.
96. [96] Nishida N, Nagahara M, Sato T, et al. Microarray analysis of colorectal cancer stromal tissue reveals upregulation of two oncogenic miRNA clusters. Clin Cancer Res, 2012, 18:3054-3070.
97. [97] Li Q, Zou C, Han Z, et al. MicroRNA-25 functions as a potential tumor suppressor in colon cancer by targeting Smad7. Cancer Lett, 2013, 335:168-174.
98. [98] Esposito F, Tornincasa M, Pallante P, et al. Down-regulation of the miR-25 and miR-30d contributes to the development of anaplastic thyroid carcinoma targeting the polycomb protein EZH2. J Clin Endocrinol Metab, 2012, 97:E710-E718.
99. [99] Zhang H, Zuo Z, Lu X, et al. miR-25 regulates apoptosis by targeting Bim in human ovarian cancer. Oncol Rep, 2012, 27:594-598.
100. [100] Wang X, Meng X, Li H, et al. MicroRNA-25 expression level is an independent prognostic factor in epithelial ovarian cancer. Clin Transl Oncol, 2014, 16:954-958.
101. [101] Feng S, Pan W, Jin Y, et al. miR-25 promotes ovarian cancer proliferation and motility by targeting LATS2. Tumour Biol, 2014, Sep 2. [Epub ahead of print].
102. [102] Wang Y, Zhang X, Li H, et al. The role of miRNA-29 family incancer. Eur J Cell Biol, 2013, 92:123-128.
103. [103] Zhang X, Zhao X, Fiskus W, et al. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas. Cancer Cell, 2012, 22:506-523.
104. [104] Maurer B, Stanczyk J, Jungel A, et al. MicroRNA-29, a key regulator of collagen expression in systemic sclerosis. Arthritis Rheum, 2010, 62:1733-1743.
105. [105] Roderburg C, Urban GW, Bettermann K, et al. Micro-RNA profiling reveals a role for miR-29 in human and murine liver fibrosis. Hepatology, 2011, 53:209-218.
106. [106] Ugalde AP, Ramsay AJ, de la Rosa J, et al. Aging and chronic DNA damage response activate a regulatory pathway involving miR-29 and p53. EMBO J, 2011, 30:2219-2232.
107. [107] Zhang JX, Mai SJ, Huang XX, et al. MiR-29c mediates epithelial-to-mesenchymal transition in human colorectal carcinoma metastasisvia PTP4A and GNA13 regulation of beta-catenin signaling. AnnOncol, 2014, 25:2196-2204.
108. [108] Han TS, Hur K, Xu G, et al. MicroRNA-29c mediates initiation ofgastric carcinogenesis by directly targeting ITGB1. Gut, 2014, pii: gutjnl-2013-306640. doi: 10.1136/gutjnl-2013-306640. [Epubahead of print].
109. [109] Bae HJ, Noh JH, Kim JK, et al. MicroRNA-29c functions as a tumorsuppressor by direct targeting oncogenic SIRT1 in hepatocellularcarcinoma. Oncogene, 2014, 33:2557-2567.
110. [110] Pierce ML, Weston MD, Fritzsch B, et al. MicroRNA-183 familyconservation and ciliated neurosensory organ expression. EvolDev, 2008, 10:106-113.
111. [111] Abraham D, Jackson N, Gundara JS, et al. MicroRNA profilingof sporadic and hereditary medullary thyroid cancer identifiespredictors of nodal metastasis, prognosis, and potential therapeutictargets. Clin Cancer Res, 2011, 17:4772-4781.
112. [112] Lin S, Sun JG, Wu JB, et al. Aberrant microRNAs expression inCD133(+)/CD326(+) human lung adenocarcinoma initiating cellsfrom A549. Mol Cells, 2012, 33:277-283.
113. [113] Xu X, Dong Z, Li Y, et al. The upregulation of signal transducerand activator of transcription 5-dependent microRNA-182 andmicroRNA-96 promotes ovarian cancer cell proliferation bytargeting forkhead box O3 upon leptin stimulation. Int J BiochemCell Biol, 2013, 45:536-545.
114. [114] Zhang QH, Sun HM, Zheng RZ, et al. Meta-analysis ofmicroRNA-183 family expression in human cancer studiescomparing cancer tissues with noncancerous tissues. Gene, 2013, 527:26-32.
115. [115] Kong WQ, Bai R, Liu T, et al. MicroRNA-182 targets cAMP-responsive element-binding protein 1 and suppresses cell growthin human gastric adenocarcinoma. FEBS J, 2012, 279:1252-1260.
116. [116] Li X, Luo F, Li Q, et al. Identification of new aberrantly expressedmiRNAs in intestinal-type gastric cancer and its clinical signifi-cance. Oncol Rep, 2011, 26:1431-1439.
117. [117] Vaksman O, Stavnes HT, Kaern J, et al. miRNA profiling alongtumour progression in ovarian carcinoma. J Cell Mol Med, 2011, 15:1593-1602.
118. [118] Liu Z, Liu J, Segura MF, et al. miR-182 overexpression intumourigenesis of high-grade serous ovarian carcinoma. J Pathol, 2012, 228:204-215.
119. [119] Wang YQ, Guo RD, Guo RM, et al. MicroRNA-182 promotes cellgrowth, invasion, and chemoresistance by targeting programmedcell death 4 (PDCD4) in human ovarian carcinomas. J CellBiochem, 2013, 114:1464-1473.
120. [120] Wang L, Zhu MJ, Ren AM, et al. A ten-microRNA signatureidentified from a genome-wide microRNA expression profiling inhuman epithelial ovarian cancer. PLoS One, 2014, 9:e96472.
121. [121] Yang D, Khan S, Sun Y, et al. Association of BRCA1 and BRCA2mutations with survival, chemotherapy sensitivity, and genemutator phenotype in patients with ovarian cancer. JAMA, 2011, 306:1557-1565.
122. [122] Qu Y, Li WC, Hellem MR, et al. miR-182 and miR-203 inducemesenchymal to epithelial transition and self-sufficiency of growthsignals via repressing SNAI2 in prostate cells. Int J Cancer, 2013, 133:544-555.
123. [123] Chiang CH, Hou MF, Hung WC. Up-regulation of miR-182 bybeta-catenin in breast cancer increases tumorigenicity andinvasiveness by targeting the matrix metalloproteinase inhibitorRECK. Biochim Biophys Acta, 2013, 1830:3067-3076.
124. [124] Qiu Y, Luo X, Kan T, et al. TGF-beta upregulates miR-182expression to promote gallbladder cancer metastasis by targetingCADM1. Mol Biosyst, 2014, 10:679-685.
125. [125] Donnem T, Fenton CG, Lonvik K, et al. MicroRNA signaturesin tumor tissue related to angiogenesis in non-small cell lungcancer. PLoS One, 2012, 7:e29671.
126. [126] Sachdeva M, Mito JK, Lee CL, et al. MicroRNA-182 drivesmetastasis of primary sarcomas by targeting multiple genes. J ClinInvest, 2014, 124:4305-4319.
127. [127] Smirnova L, Grafe A, Seiler A, et al. Regulation of miRNAexpression during neural cell specification. Eur J Neurosci, 2005, 21:1469-1477.
128. [128] Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer’sdisease hippocampus. Neuroreport, 2007, 18:297-300.
129. [129] Baskerville S, Bartel DP. Microarray profiling of microRNAs revealsfrequent coexpression with neighboring miRNAs and host genes. RNA, 2005, 11:241-247.
130. [130] Corcoran DL, Pandit KV, Gordon B, et al. Features of mammalianmicroRNA promoters emerge from polymerase II chromatinimmunoprecipitation data. PLoS One, 2009, 4:e5279.
131. [131] Monteys AM, Spengler RM, Wan J, et al. Structure and activity ofputative intronic miRNA promoters. RNA, 2010, 16:495-505.
132. [132] Muinos-Gimeno M, Montfort M, Bayes M, et al. Design andevaluation of a panel of single-nucleotide polymorphisms inmicroRNA genomic regions for association studies in humandisease. Eur J Hum Genet, 2010, 18:218-226.
133. [133] Mi S, Lu J, Sun M, et al. MicroRNA expression signaturesaccurately discriminate acute lymphoblastic leukemia from acutemyeloid leukemia. Proc Natl Acad Sci U S A, 2007, 104:19971-19976.
134. [134] Donzelli S, Fontemaggi G, Fazi F, et al. MicroRNA-128-2 targetsthe transcriptional repressor E2F5 enhancing mutant p53 gain offunction. Cell Death Differ, 2012, 19:1038-1048.
135. [135] Karimi M, Conserva F, Mahmoudi S, et al. Extract from AsteraceaeBrachylaena ramiflora induces apoptosis preferentially inmutant p53-expressing human tumor cells. Carcinogenesis, 2010, 31:1045-1053.
136. [136] Volinia S, Calin GA, Liu CG, et al. A microRNA expressionsignature of human solid tumors defines cancer gene targets. ProcNatl Acad Sci U S A, 2006, 103:2257-2261.
137. [137] Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expressionprofile in undifferentiated gastric cancer. Int J Oncol, 2009, 34:537-542.
138. [138] Khan AP, Poisson LM, Bhat VB, et al. Quantitative proteomicprofiling of prostate cancer reveals a role for miR-128 in prostatecancer. Mol Cell Proteomics, 2010, 9:298-312.
139. [139] Woo HH, Laszlo CF, Greco S, et al. Regulation of colonystimulating factor-1 expression and ovarian cancer cell behavior invitro by miR-128 and miR-152. Mol Cancer, 2012, 11:58.
140. [140] Qian P, Banerjee A, Wu ZS, et al. Loss of SNAIL regulated miR-128-2 on chromosome 3p22.3 targets multiple stem cell factors to promote transformation of mammary epithelial cells. Cancer Res, 2012, 72:6036-6050.
141. [141] Evangelisti C, Florian MC, Massimi I, et al. miR-128 up-regulation inhibits Reelin and DCX expression and reduces neuroblastomacell motility and invasiveness. FASEB J, 2009, 23:4276-4287.
142. [142] Shahab SW, Matyunina LV, Hill CG, et al. The effects of microRNA transfections on global patterns of gene expression in ovarian cancer cells are functionally coordinated. BMC Med Genomics, 2012, 5:33.